Funding Update: 2013 – 2015
September 10, 2013
1
China 2013
2
OVERVIEW
• MR Initiative Annual Expenditure 2001-2013
• MR Initiative Annual Donations 2001-2013;
Financial Resource Requirements through 2015
• MR Initiative Financial Resource Requirements - detail
• MR Initiative donors, 2001 - 2013
• measles & rubella moving ahead
• Challenges to implementation for MR Initiative
3
MR Initiative Annual Expenditure,
2001-2013
180
160
Total expenditure 2001-2013 = $1,008 million
$ US Million
140
120
100
80
60
40
20
0
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Donations
* Excluding country contributions
Series2
4
Measles & Rubella Initiative Annual Donations
2001-2015 and Financial Resource Requirements,
Projections, Funding Gap 2013-2015*
350
94
300
$ US Million
250
59
11
200
36
38
44
150
100
50
0
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Donations
Funds Projected or Pledged
* Excludes all country contributions and direct social mobilization funding from partners
Funding gap (includes PSC)
5
Measles & Rubella Initiative Financial Resource
Requirements, Projections, Funding Gap 2013-2015
47
Total Funding Gap 2014-2015: US $65 million
400
350
32
18
$ US Million
300
31
250
200
150
100
50
0
2013
2014
Anticipated Country Contributions
Donor Funds Projected/Pledged/Received
2015
Anticipated GAVI Contribution (Rubella)
Funding Gap (includes PSC)
6
Resource Requirements by Major Category of Activity,
2014-2015
Total Cost 2014-2015: US $557 million
400
350
$US Million
300
250
200
150
100
50
0
2014
2015
Measles SIAs
Measles Rubella SIAs
Technical Assistance
Outbreak Response
Surveillance / Lab
Coverage Surveys
Research
Communication
7
MR Initiative Donors, 2001-2013
CDC
JICA
Norway
DFID
Civil Society
ARC*
LDS
Lions
UN
UNICEF
UNF*
Foundations
Gates
Private Sector
BD
Merck
Vodaphone
Other
GAVI/IFFIm
8
* Includes ARC/UNF and other partners
Where is the Measles & Rubella Initiative Headed?
Toward regional achievement of Measles Rubella Elimination Goals by or before 2020
Improvement of routine coverage and timely and high quality SIAs
Expanded use of accurate data for decision making
•
•
•
•
2012 measles goals: AFRO (pre-elimination) and WPRO (elimination) - missed
2013 potential SEARO elimination goal set (waiting), begin MR introduction
campaigns with GAVI support (done)
2015 GIVS (95% mortality reduction) and MDG 4 goals; measles goal in EMRO
and EURO (elimination); rubella goal in EURO (elimination); continue to set
regional rubella elimination goals as appropriate
2020 Measles goal in AFRO (elimination)
Critical Elements for Success
• Political leadership
• Timely funding (donor and national governments)
• Adequate time for planning and social mobilization (9 months)
• Well performing surveillance, analysis & use of data to improve coverage
9
Challenges to Implementation for
MR Initiative
• Lack of timely and sufficient funding: few multiyear grants
• Ensuring high quality SIA’s (increased training and social mobilization
cost, increased technical assistance request)
• Providing strategic support for non-GAVI eligible countries (TA, Surveillance)
• Increased surveillance cost (including lab, coverage surveys)
• Projecting target age range for SIA’s several years in advance
• Projecting cost to MR Initiative for target populations above 59 months
for GAVI funded measles SIA’s in 6 large countries
• Routine immunization: scale up of MCV1, increased MCV2 introduction
and coverage, other routine strengthening immunization activities
10
Anne Ray Charitable Trust
11